Fig. 4From: Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover studyFEV1 assessments in Study 1222.27: adjusted mean FEV1 trough response at week 4. QD: once daily; BID: twice daily; PFT: pulmonary function test; FEV1: forced expiratory volume in 1 sBack to article page